The Oncotype DX Breast Recurrence Score® test has been validated in multiple clinical trials and is recommended by the UK’s National Institute for Health and Care Excellence (NICE)1 which provides national guidance and advice to improve health and social care in England and Wales. With use in over 1 million people worldwide, the test has also been incorporated into all major international guidelines for clinical practice and treatment in breast cancer.2-6
The Oncotype DX Breast Recurrence Score® test is a genomic test performed on the tumour tissue removed from your breast either when you have a biopsy or you have surgery which means no additional procedure is needed.
You may be a candidate for the Oncotype DX® test if you:
are newly diagnosed with early-stage invasive breast cancer: stage I, II and in some cases of stage III (See glossary);
have cancer that is Hormone (oestrogen and/or progesterone) Receptor-positive (HR+/ER+);
have cells that are Human Epidermal growth factor Receptor 2-negative (HER2-);
are either lymph node negative, 1–3 lymph node positive or have micrometastases (See glossary) in the lymph nodes.
If eligible, why should I have the test?
The Oncotype DX test provides insight into your tumour biology that is not available from traditional measures. More specifically, you and your doctor will receive individualised information as to whether adding chemotherapy to hormone therapy may reduce the risk the cancer returns. Without this test, doctors can only estimate how likely a patient’s cancer is to return by looking at factors such as age, tumour size, tumour grade, and lymph node status.
It is important that that your tumour tissue sample be tested before you start any treatment (hormone therapy or chemotherapy). Talk to your doctor and assess whether you are eligible for testing with the Oncotype DX Breast Recurrence Score test.
The decision of chemotherapy
Chemotherapy can be a life-saving treatment however it comes with many short and long-term side effects7. Consequently, the decision to receive chemotherapy can be difficult for many breast cancer patients and it must be discussed and considered carefully with your doctor.
The Oncotype DX Breast Recurrence Score® test provides your Recurrence Score® result, which is a number between 0 and 100, specific to your tumour. This will help in discussions you will have with your healthcare professional about the need for chemotherapy treatment.
Availability of the Oncotype DX® test in UK health services
The Oncotype DX test® is available for patients treated in the NHS and it is also reimbursed by all major insurance companies for all patients with ER+, HER2- early stage, invasive breast cancer both lymph node negative and lymph node positive 1-3 positive nodes.
With the Oncotype DX test®, you and your doctor can better understand what treatment options are right for you and avoid overtreatment with aggressive therapies like chemotherapy. If you think you are a candidate, don’t hesitate to speak to your doctor about the possibility of having the test.